Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
"While Ozempic is well covered in the U.S., let's not forget that there are some patients who pay out-of-pocket for this vital medicine," Dave Moore, executive vice president of Novo Nordisk's U.S
For individuals managing chronic conditions, the appeal of micro-dosing lies in its sustainability
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), pancreatitis can cause severe upper abdominal pain that may spread to the back, along with nausea and vomiting
While bariatric procedures such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy produce substantial initial weight loss, physiological adaptations and behavioral factors can contribute to gradual weight recurrence
It exists in blood platelets, skeletal muscle, the kidneys, and the retina
